Granted Patent
B2
US 10,857,150 · App. 16/349,757 · Granted Dec 8, 2020
Use of sanglifehrin macrocyclic analogues as anticancer compounds
Inventors:
Alvar Gronberg (Knivsta, SE); Magnus Joakim Hansson (Landskrona, SE); Matthew Alan Gregory (Bourn, GB); Steven James Moss (Balsham, GB)
Assignee:
ABLIVA AB
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.
Claims (3)
1. A sanglifehrin analogue having the structure
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a sanglifehrin analogue as defined in claim 1 together with one or more pharmaceutically acceptable excipients.
Assignments (2)
CHANGE OF NAME
Recorded Oct 15, 2020
From: NEUROVIVE PHARMACEUTICAL AB
To: ABLIVA AB
Reel/Frame 054088/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 19, 2019
From: GRONBERG, ALVAR; HANSSON, MAGNUS JOAKIM; GREGORY, MATTHEW ALAN; MOSS, STEVEN JAMES
To: NEUROVIVE PHARMACEUTICAL AB
Reel/Frame 049522/0121 →
Priority Claims (2)
DK 2016 70920
· Nov 18, 2016
· national
DK 2017 70054
· Jan 30, 2017
· national
Continuity (1)